tirzepatide side effects muscle loss Mounjaro (Tirzepatide) Effects: Your Month-by-Month Guide GLP-1 and Muscle Loss: Semaglutide,

Revised: 1/2026 PACKAGE/LABEL PRINCIPAL DISPLAY PANEL OZEMPIC 1.5 mg tablets NDC 0169-1715-30List 171530 OZEMPIC 1.5 mg (semaglutide) Tablets 1.5 mg Rx only DISPENSE WITH MEDICATION GUIDE Note to Pharmacist: Individual strengths of semaglutide are not substitutable on a mg-to-mg basis New Formulation of semaglutide 30 tablets PACKAGE/LABEL PRINCIPAL DISPLAY PANEL OZEMPIC 4 mg tablets NDC 0169-1704-30List 170430 OZEMPIC 4 mg (semaglutide) Tablets 4 mg Rx only DISPENSE WITH MEDICATION GUIDE Note to Pharmacist: Individual strengths of semaglutide are not substitutable on a mg-to-mg basis New Formulation of semaglutide 30 tablets PACKAGE/LABEL PRINCIPAL DISPLAY PANEL OZEMPIC 9 mg tablets NDC 0169-1709-30List 170930 OZEMPIC 9 mg (semaglutide) Tablets 9 mg Rx only DISPENSE WITH MEDICATION GUIDE Note to Pharmacist: Individual strengths of semaglutide are not substitutable on a mg-to-mg basis New Formulation of semaglutide 30 tablets PACKAGE/LABEL PRINCIPAL DISPLAY PANEL RYBELSUS 3 mg bottle NDC 0169-4303-30List 430330 RYBELSUS 3 mg (semaglutide) Tablets 3 mg Once daily Oral use only Rx only DISPENSE WITH MEDICATION GUIDE 30 tablets PACKAGE/LABEL PRINCIPAL DISPLAY PANEL RYBELSUS 7 mg bottle NDC 0169-4307-30List 430730 RYBELSUS 7 mg (semaglutide) Tablets 7 mg Once daily Oral use only Rx only DISPENSE WITH MEDICATION GUIDE 30 tablets PACKAGE/LABEL PRINCIPAL DISPLAY PANEL RYBELSUS 14 mg bottle NDC 0169-4314-30List 431430 RYBELSUS 14 mg (semaglutide) Tablets 14 mg Once daily Oral use only Rx only DISPENSE WITH MEDICATION GUIDE 30 tablets PACKAGE/LABEL PRINCIPAL DISPLAY PANEL RYBELSUS 3 mg blister NDC 0169-4303-13List 430313 RYBELSUS3 mg (semaglutide) Tablets 3 mg Once daily Each tablet contains 3 mg semaglutide Oral use only Rx only Dispense the Enclosed Medication Guide to Each Patient 30 tablets 3 blister packs

Third, ensure equity and accessibility

Which one is right

Endokrynol Pol 67:567571 Seitz R, Tmen D, Kunst C et al (2024) Exploring the thioredoxin system as a therapeutic target in cancer: mechanisms and implications